Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatme⦠read more
Healthcare
Biotechnology
25 years
USD
Exclusive to Premium users
$145.10
Price+1.80%
$2.57
$30.671b
Large
-
Premium
Premium
-275.1%
EBITDA Margin-299.5%
Net Profit Margin-194.6%
Free Cash Flow Margin$398.105m
+9.5%
1y CAGR+17.7%
3y CAGR+20.8%
5y CAGR-$1.034b
-13.2%
1y CAGR-30.2%
3y CAGR-25.4%
5y CAGR-$5.71
-2.5%
1y CAGR-14.5%
3y CAGR-11.0%
5y CAGR$1.250b
$2.480b
Assets$1.230b
Liabilities$575.508m
Debt23.2%
-0.6x
Debt to EBITDA-$868.567m
-23.1%
1y CAGR-28.5%
3y CAGR-24.0%
5y CAGR